Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The transition in practice: policy makers and purchasers

B Bevan1

  • 1Hammersmith & Hounslow Health Authority, UK.

British Journal of Clinical Practice. Supplement
|May 1, 1997
PubMed
Summary

The UK is phasing out chlorofluorocarbons (CFCs) in metered dose inhalers by 1999. A coordinated strategy is crucial for a smooth transition, prioritizing patient confidence in their medication.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A plate method of antibiotic assay with Mycobacterium tuberculosis 607 and Brucella abortus.

Antibiotics & chemotherapy (Northfield, Ill.)·2014
Same author

Mechanisms involved in iontophoretic transport of angiotensin.

Pharmaceutical research·1995
Same author

Reference services for a wellness program.

Medical reference services quarterly·1986
Same author

A family showing independent segregation of Bua and Ytb.

Vox sanguinis·1970
Same author

Anti-P associated with liver-fluke infection.

Vox sanguinis·1970
Same author

Comparison of qucik and slow thaw methods of producing cryoprecipitate antihaemophilic factor from fresh and 24-hour-old blood.

Journal of clinical pathology·1969

Area of Science:

  • Environmental Science
  • Pharmaceutical Science
  • Public Health

Background:

  • Chlorofluorocarbons (CFCs) are being phased out of medicinal products in the UK by the end of 1999.
  • The transition to CFC-free metered dose inhalers (pMDIs) is mandatory and requires strategic planning.
  • Patient confidence in medication must be maintained throughout this transition.

Purpose of the Study:

  • To outline a strategy for the transition to CFC-free pMDIs.
  • To identify factors critical for a smooth transition process.
  • To emphasize the role of national and local drivers in managing the change.

Main Methods:

  • Review of regulatory requirements for CFC phase-out.
  • Analysis of stakeholder roles (pharmaceutical industry, health authorities, health professionals).
  • Identification of key considerations for patient support and medication confidence.

Main Results:

  • A comprehensive strategy is necessary for health professionals and patients.
  • Collaborative efforts are essential for minimizing patient disruption.
  • Patient confidence is the primary focus during the transition.

Conclusions:

  • The transition to CFC-free pMDIs necessitates a proactive and collaborative approach.
  • Effective communication and patient support are vital for successful implementation.
  • Maintaining patient trust in inhaler devices is paramount for continued respiratory care.

Related Experiment Videos